hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06346431 id: 20240301 briefTitle: Efficacy of Digital Problem Solving Application in Reduction of Anxiety, Depression and Substance Use Disorder Symptoms acronym: Efficacy overallStatus: NOT_YET_RECRUITING date: 2026-03 date: 2026-11 date: 2026-12 date: 2024-04-04 date: 2024-04-04 name: 7 Generation Games class: INDUSTRY briefSummary: The focus of this study is the impact of usage of a mobile application to support problem-solving therapy on symptoms of anxiety, depression and substance use. conditions: Anxiety conditions: Depressive Symptoms conditions: Substance Use Disorders studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: DSPT - Digital Support for Problem-solving Therapy measure: Generalized Anxiety Disorder Scale-7 measure: Center for Epidemiological Studies Depression Scale measure: Drug Abuse Screening Test measure: Michigan Alcohol Screening Test sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT hasResults: False
nctId: NCT06346418 id: PNRR-MR1-2022-12376622 briefTitle: Maternal Genes and Epimutations: Beckwith-Wiedemann Syndrome & Reproductive Risks overallStatus: RECRUITING date: 2023-05-19 date: 2025-01 date: 2025-05 date: 2024-04-04 date: 2024-04-04 name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico class: OTHER name: Istituto Auxologico Italiano name: Università degli Studi della Campania Luigi Vanvitelli name: Federico II University briefSummary: Pathogenic variants in subcortical maternal complex (SCMC) have been identified not only in mothers of Beckwith-Wiedemann syndrome (BWS) babies but also in women with reproductive disturbances such as failed pregnancy attempts and recurrent pregnancy loss. Based on the higher incidence of BWS in children born from Assisted Reproductive Technology (ART), this project aims to investigate incidence and molecular mechanism of pathogenic variants of SCMC in women with reproductive disorders. Study objectives will be (i) assess the incidence of these variants as a cause of differences in reproductive outcomes in the infertile female population and mothers of children with BWS; (ii) identify methylation changes in women with reproductive problems including those with offspring affected by BWS; (iii) determine the molecular causes underlying female infertility and imprinting disorder associated with damaging SCMC gene variants by employing a mouse model. conditions: Beckwith-Wiedemann Syndrome studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: NONE count: 208 type: ESTIMATED name: WES analysis name: whole-genome methylation analysis measure: MEG Incidence measure: Compare DNA methylation sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico status: RECRUITING city: Milan zip: 20122 country: Italy name: Edgardo Somigliana, PhD role: CONTACT phone: +390255034303 email: edgardo.somigliana@policlinico.mi.it lat: 45.46427 lon: 9.18951 facility: Istituto Auxologico Italiano status: RECRUITING city: Milan zip: 20145 country: Italy name: Silvia Russo, Phd role: CONTACT phone: +393493237520 email: s.russo@auxologico.it lat: 45.46427 lon: 9.18951 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2022-12-20 uploadDate: 2024-03-28T05:11 filename: Prot_SAP_000.pdf size: 817568 hasResults: False
nctId: NCT06346405 id: 10 briefTitle: Central Serous Chorioretinopathy and Micropulse Laser Treatment acronym: LEVEO overallStatus: RECRUITING date: 2023-05-31 date: 2025-05-31 date: 2025-05-31 date: 2024-04-04 date: 2024-04-04 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: To evaluate choroidal and choriocapillaris changes in patients with central serous chorioretinopathy, undergone sub threshold micropulse laser treatment, following any improvement with conservative therapy with Acetazolamide and/or Eplerenone conditions: Central Serous Chorioretinopathy studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 36 type: ESTIMATED name: Subthreshold Micropulse Laser Treatment measure: Vessel density changes measure: Choroidal thickness measure: Choroidal thickness and vessel density measure: Qualitative analysis of retino-choroidal vascularization with identification of vascular pattern measure: Metamorphopsia measure: Metamorphopsia and BCVA measure: Ellipsoid Zone Integrity measure: Improvement in retinal function measure: Quality of life (QoL) measure: Ellipsoid zone and BCVA sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione Policlinico Agostino Gemelli, IRCCS status: RECRUITING city: Roma state: R zip: 00168 country: Italy name: Maria Cristina Savastano, MD, PhD role: CONTACT phone: (+39)063015 email: mariacristinasavastano@policlinicogemelli.it lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06346392 id: D9802C00001 briefTitle: AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 overallStatus: RECRUITING date: 2024-03-04 date: 2026-04-10 date: 2026-10-09 date: 2024-04-04 date: 2024-04-04 name: AstraZeneca class: INDUSTRY briefSummary: The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2. conditions: Gastric Cancer conditions: Gastroesophageal Junction Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be randomized in a 1:1:1 ratio to one of the following intervention arms until the dose selection decision is made:
nctId: NCT06346379 id: 2023-K086-01 briefTitle: The Effect of Baduanjin on Physical Fitness and Bone Density in Maintenance Hemodialysis Patients overallStatus: RECRUITING date: 2024-04-01 date: 2024-05-01 date: 2025-10-01 date: 2024-04-04 date: 2024-04-19 name: Affiliated Hospital of Nantong University class: OTHER briefSummary: The aim of this study is to examine the effect of 12-month Baduanjin exercise on physical fitness and bone density in maintenance hemodialysis (MHD) patients. 50 MHD patients aged 18-75 will included in this study and randomly divided into two groups (intervention group and control group). The intervention group will be led by a professional person and underwent Baduanjin exercise three times a week before hemodialysis. The control group maintained routine treatment and daily activities. conditions: Rehabilitation conditions: Physical Fitness conditions: Bone Density conditions: Hemodialysis Complication studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: Baduanjin exercise measure: Muscle strength measurement measure: Five-times Sit-to-Stand Test (FTSST) measure: Timed "up and go" test (TUGT) measure: The sitting forward flexion test measure: The Standing on one-leg with eyes closed test (SOLECT) measure: Bone mineral density test measure: Changes in the Short Form-36(SF-36) measure: Changes in the Hospital Anxiety and Depression Scale （HADS） measure: European Quality of Life Five Dimension（EQ-5D-5L) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Affiliated Hospital of Nantong University status: RECRUITING city: Nantong state: Jiangsu zip: 226000 country: China name: Li Yuan role: CONTACT phone: 0086-051381168416 email: yuanlint@163.com name: Yuan Zhang role: CONTACT phone: 0086-051381168411 email: 49260183@qq.com lat: 32.03028 lon: 120.87472 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-07-10 uploadDate: 2024-03-18T04:22 filename: Prot_SAP_000.pdf size: 179776 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-07-10 uploadDate: 2024-03-28T03:53 filename: ICF_001.pdf size: 247762 hasResults: False
nctId: NCT06346366 id: NL.82557.018.22 briefTitle: Glucose Control Through a Bihormonal Artificial Pancreas in Patients After Total Pancreatectomy acronym: PANORAMA overallStatus: ACTIVE_NOT_RECRUITING date: 2023-04-25 date: 2024-04-01 date: 2024-04-01 date: 2024-04-04 date: 2024-04-04 name: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) class: OTHER briefSummary: In recent years total pancreatectomy is increasingly performed in selected patients due to the increasing use of preoperative chemotherapy, making more patients operable. After total pancreatectomy, all patients develop insulin dependent diabetes mellitus (IDDM). Glucose control in these patients is challenging due to the complete absence of both pancreatic insulin and glucagon secretion, and most patients report decreased quality of life due to fear of hypoglycemic events and the need for continuous glucose monitoring.
The CE marked bihormonal artificial pancreas (BIHAP) provides continuous fully automatic glucose monitoring and administration of insulin and glucagon using a self-learning algorithm. In a recent pilot study (APPEL5+, NL.8871) the BIHAP was being compared to current diabetes treatment in 10 patients after total pancreatectomy. This trial demonstrated that treatment with BIHAP was safe and improved time spent in euglycemia significantly during one week treatment (78.30%, \[IQR 71.05%-82.61%\] vs. 57.38% \[IQR 52.38%-81.35%\], p=0.03).
The PANORAMA trial will evaluate the efficacy of a 3-month treatment with BIHAP in 40 patients after total pancreatectomy as compared to a 3-month treatment period with current diabetes care in a randomized cross-over trial. Patients will be randomized to start with the BIHAP (after a training period) or current diabetes care (i.e. insulin pen or pump). Hereafter, all patients will cross over. conditions: Pancreatic Neoplasms conditions: Type 3c Diabetes conditions: Total Pancreatectomy studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Patients are randomized to a 3-month treatment period with the bihormonal artificial pancreas (BIHAP) (preceded by a training period) or a 3-month treatment with their current diabetes care. Hereafter, all patients will cross over. primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Bihormonal artificial pancreas (BIHAP) / closed loop measure: Time in range measure: Efficacy of open and closed loop system measure: Efficacy of open and closed loop system measure: Efficacy of open and closed loop system measure: Efficacy of open and closed loop system measure: Efficacy of open and closed loop system measure: Adverse events and device issues associated with closed loop system with BIHAP measure: Patient reported outcomes on quality of life - WHO-5 measure: Patient reported outcomes on quality of life - EQ-5D-5L measure: Patient reported outcomes on quality of life - DTSQc andDTSQs measure: Patient reported outcomes on quality of life - PAID-20 measure: Patient reported outcomes on quality of life - HFS-II measure: Patient reported outcomes on quality of life - PSQI measure: Patient reported outcomes on quality of life - INSPIRE measure: Patient reported outcomes on quality of life - Hypoglycaemia unawareness measure: Patient reported outcomes on quality of life - benefits and disadvantages of BIHAP treatment measure: Other treatment endpoints - daily insulin and glucagon use measure: Other treatment endpoints - activity of BIHAP algorithm measure: Other treatment endpoints - daily insulin use measure: Other treatment endpoints - treatment related actions measure: Other treatment endpoints - demographics measure: Other treatment endpoints - demographics measure: Other treatment endpoints - concomitant medication sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Amsterdam UMC city: Amsterdam zip: 1081 HV country: Netherlands lat: 52.37403 lon: 4.88969 hasResults: False
nctId: NCT06346353 id: Chess Cognition SUD briefTitle: Substance Consumption, Personality, and Cognitive Functioning of Chess Players overallStatus: RECRUITING date: 2024-01-31 date: 2024-05-31 date: 2024-05-31 date: 2024-04-04 date: 2024-04-04 name: Central Institute of Mental Health, Mannheim class: OTHER briefSummary: The aim of this project is to find out if there is a difference in addictive behavior, personality traits, and cognitive abilities between chess players and non-chess players. conditions: Addiction conditions: Alcohol conditions: Nicotine conditions: Drugs conditions: Personality conditions: Depression conditions: Anxiety studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 910 type: ESTIMATED measure: Substance Craving measure: Alcohol Use measure: Automatic Alcohol Craving measure: Severity of Nicotine Dependence measure: Automatic Cigarette Craving measure: Smoking Consequences measure: Drug Abuse measure: Personality measure: Depression measure: Anxiety measure: self-efficacy measure: coping with stress measure: Inhibition capacity measure: Working Memory capacity sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Klinik für Abhängiges Verhalten, Zentralinstitut für Seelische Gesundheit status: RECRUITING city: Mannheim country: Germany name: Sabine Vollstädt-Klein role: CONTACT lat: 49.4891 lon: 8.46694 hasResults: False
nctId: NCT06346340 id: 936 briefTitle: A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-11 date: 2024-09 date: 2024-09 date: 2024-04-04 date: 2024-04-04 name: Bausch & Lomb Incorporated class: INDUSTRY briefSummary: A Phase 4, Multicenter, Open-Label Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/ Keratometry and Postoperative Refractive Accuracy conditions: Dry Eye studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Miebo measure: Mean difference between absolute deviations from predicted refractive error in the study eye. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Site 105 city: Laguna Hills state: California zip: 92655 country: United States lat: 33.61252 lon: -117.71283 facility: Site 102 city: Petaluma state: California zip: 92954 country: United States lat: 38.23242 lon: -122.63665 facility: Site 103 city: Largo state: Florida zip: 33770 country: United States lat: 27.90979 lon: -82.78842 facility: Site 104 city: Saint Louis state: Missouri zip: 63131 country: United States lat: 38.62727 lon: -90.19789 facility: Site 101 city: Somersworth state: New Hampshire zip: 03878 country: United States lat: 43.26175 lon: -70.86534 hasResults: False
nctId: NCT06346327 id: Absent End-Diastolic Flow briefTitle: Clinical Significance Of Intermittently Absent End-Diastolic Flow Of The Fetal Umbilical Artery On Perinatal And Neonatal Outcomes Dr. Zeynep Kayaoğlu Yıldırım Dr. Alperen İnce Dr Gökhan Bayanmelek Dr Gökhan Bolluk overallStatus: COMPLETED date: 2020-06-01 date: 2023-08-31 date: 2023-10-30 date: 2024-04-04 date: 2024-04-04 name: Başakşehir Çam & Sakura City Hospital class: OTHER_GOV briefSummary: Objective: This study aimed to estimate the risk of adverse perinatal outcomes among pregnant patients with intermittently absent (iAEDF) and persistently absent end-diastolic umbilical artery flow (pAEDF). The fetal risks associated with persistently absent end-diastolic flow have been described. However, the risks associated with intermittent absent end-diastolic flow are not well-known.
Study design: We performed a retrospective cohort study of patients diagnosed with the iAEDF or pAEDF at our institution from 2020 to 2023. Fetuses were classified under two categories: iAEDF group and pAEDF group.Neonatal outcomes, demographic information, pregnancy outcomes and pregnancy complications were compared between patients with iAEDF and those with pAEDF. conditions: Absent End-Diastolic Flow Of The Fetal Umbilical Artery studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 137 type: ACTUAL measure: neonatal outcomes measure: latency from the time of absent endiastolic flow diagnosis to delivery measure: pregnancy complications (Number of Pregnancies complicated with IUMF, ablatio placenta, fetal distress, Intrauterine growth restriction and amniotic fluid abnormalities). sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: İstanbul Başakşehir Çam ve Sakura City Hospital city: Istanbul state: Türkiye zip: 34480 country: Turkey lat: 41.01384 lon: 28.94966 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-11-08 uploadDate: 2024-04-02T18:47 filename: Prot_SAP_000.pdf size: 410898 hasResults: False
nctId: NCT06346314 id: 12241976 briefTitle: Is There an Immediate Effect on Pectoralis Minor Length After Performing a Prone Scapular Retraction Exercise overallStatus: COMPLETED date: 2021-07-15 date: 2022-01-10 date: 2022-01-10 date: 2024-04-04 date: 2024-04-04 name: Andrews University class: OTHER briefSummary: The goal of this clinical trial is to test normal participants.
• Do the participant's pectoralis minor muscles change length immediately after performing an exercise that recruits the scapular retractor muscles? Participants will have their pectoralis minor muscle measured, then perform an exercise recruiting the scapular retractor muscles, and then have their pectoralis muscle measured again. conditions: Pectoralis Minor Length studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 50 type: ACTUAL name: Scapular retraction exercise measure: Pectoralis Minor Length sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: North Idaho Physical Therapy city: Hayden state: Idaho zip: 83835 country: United States lat: 47.76602 lon: -116.78658 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-11-30 uploadDate: 2023-11-30T13:36 filename: Prot_SAP_000.pdf size: 341703 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2021-04-19 uploadDate: 2024-03-12T17:52 filename: ICF_001.pdf size: 286800 hasResults: False
nctId: NCT06346301 id: NL83374.018.23 briefTitle: Imagery Rescripting as a Stand-alone Treatment for OCD and BDD. overallStatus: RECRUITING date: 2023-04-21 date: 2026-01 date: 2027-01 date: 2024-04-04 date: 2024-04-04 name: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) class: OTHER briefSummary: The goal of this multiple baseline case series study is to test the effect of imagery rescripting (ImRs) in Obsessive Compulsive Disorder (OCD) and Body Dysmorphic Disorder (BDD).
Participants will rate schema- or core beliefs and OCD or BDD severity on a visual analogue scale. In addition participants will rate core emotions, affect and obtrusiveness of the intrusion. Secondary we will asses four times questionnaires about OCD of BDD symptoms, depression and schemas en modes. After treatment participants will be interviewed about their experiences. conditions: Obsessive-Compulsive Disorder conditions: Body Dysmorphic Disorders conditions: Anxiety Disorders studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Multiple baseline case series design: Patients wil be randomized to different lengths of baseline period and the effectiveness of the treatment is tested by comparing means and slopes of daily reported schema- or core beliefs and OCD and BDD severity, primaryPurpose: TREATMENT masking: NONE count: 36 type: ESTIMATED name: Imagery rescripting measure: Schema of core beliefs measure: Obsessive Compulsive (OCD) and Body Dysmorphic (BDD)symptoms measure: Core Emotions, affect strength, obtrusiveness of intrusion. measure: Yale Brown Obsessive Compulsive Scale (Y-BOCS(-BDD)) measure: Hamilton Depression Rating Scale (HDRS) measure: Young Schema Questionnaire (YSQ) and Schema Mode Inventory (SMI) measure: Qualitative interview sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Psychiatry, AMC status: RECRUITING city: Amsterdam-Zuidoost state: Noord-Holland zip: 1105 AZ country: Netherlands name: Tibor van Verseveld role: CONTACT phone: +31619624228 email: t.r.vanverseveld@amsterdamumc.nl lat: 52.3075 lon: 4.97222 typeAbbrev: Prot_SAP_ICF hasProtocol: True hasSap: True hasIcf: True label: Study Protocol, Statistical Analysis Plan, and Informed Consent Form date: 2023-06-23 uploadDate: 2024-02-27T15:21 filename: Prot_SAP_ICF_000.pdf size: 672806 hasResults: False
nctId: NCT06346288 id: M24-144 briefTitle: A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease overallStatus: NOT_YET_RECRUITING date: 2024-05-06 date: 2025-01-20 date: 2025-05-27 date: 2024-04-04 date: 2024-04-24 name: AbbVie class: INDUSTRY briefSummary: Inflammatory bowel disease (IBD) is a chronic inflammatory disease that requires lifelong treatment. This study will asses the concentrations of risankizumab in the breast milk of lactating women with IBD
Participants will attend regular visits during the study at a hospital or clinic. The participants will also be completing questionnaires and will have medical assessments, checking for side effects. conditions: Inflammatory Bowel Disease studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: The study will only include lactating women who are receiving treatment with risankizumab for IBD in accordance with their treating physician, although this study is non-interventional regarding treatment with risankizumab, it is considered interventional due to the collection of breast milk from the lactating mothers. primaryPurpose: OTHER masking: NONE count: 10 type: ESTIMATED name: Breast Milk Sampling name: Risankizumab measure: To determine the concentration of risankizumab in breastmilk sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06346275 id: 3rdZhejiangCMU-11 briefTitle: Effect of Acupuncture on the Gait Disturbance and Hemodynamic Changes in the Prefrontal Cortex overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2025-04 date: 2025-04 date: 2024-04-04 date: 2024-04-04 name: The Third Affiliated hospital of Zhejiang Chinese Medical University class: OTHER briefSummary: Background: Alzheimer's disease (AD) is characterized by cognitive impairment and behavioral impairment, and increasing attention is paid in the gait of AD patients. The aim of this randomized controlled trial (RCT) is to explore the effect of acupuncture on the cognitive function, gait performance, and hemodynamic changes in the prefrontal cortices.
Discussion: This trial is expected to explore the effect of acupuncture on cognitive function, gait performance, and hemodynamic changes in the prefrontal cortices for AD patients. conditions: Alzheimer Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 108 type: ESTIMATED name: Acupuncture measure: Three-dimensional gait analysis measure: Cerebral hemodynamics measure: Mini-Mental State Examination measure: Montreal Cognitive Assessment measure: Barthel Index sex: ALL minimumAge: 40 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False